David A Simpson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7070224/publications.pdf

Version: 2024-02-01

75 papers	6,280 citations	172457 29 h-index	82547 72 g-index
75 all docs	75 docs citations	75 times ranked	6572 citing authors

#	Article	IF	Citations
1	Zanubrutinib for treatmentâ€naÃ¯ve and relapsed/refractory chronic lymphocytic leukaemia: longâ€term followâ€up of the phase I/II AUâ€003 study. British Journal of Haematology, 2022, 196, 1209-1218.	2.5	24
2	Optimizing Optical Tweezers Experiments for Magnetic Resonance Sensing with Nanodiamonds. ACS Photonics, 2021, 8, 1214-1221.	6.6	13
3	Subgroup analysis of ICARIAâ€MM study in relapsed/refractory multiple myeloma patients with highâ€risk cytogenetics. British Journal of Haematology, 2021, 194, 120-131.	2.5	27
4	Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Advances, 2021, 5, 2577-2585.	5.2	60
5	Zanubrutinib monotherapy for patients with treatment-naÃ¯ve chronic lymphocytic leukemia and 17p deletion. Haematologica, 2021, 106, 2354-2363.	3.5	62
6	Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials. Journal of Hematology and Oncology, 2021, 14, 167.	17.0	21
7	Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia, 2020, 34, 787-798.	7.2	321
8	A practical guide to laboratory investigations at diagnosis and follow up in WaldenstrÃ¶m macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. Pathology, 2020, 52, 167-178.	0.6	23
9	Electrospun Nanodiamondâ€“Silk Fibroin Membranes: A Multifunctional Platform for Biosensing and Wound-Healing Applications. ACS Applied Materials & Interfaces, 2020, 12, 48408-48419.	8.0	50
10	Zanubrutinib for the treatment of patients with WaldenstrÃ¶m macroglobulinemia: 3 years of follow-up. Blood, 2020, 136, 2027-2037.	1.4	78
11	A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Haematologica, 2020, 105, e164-e168.	3.5	5
12	Enhanced Widefield Quantum Sensing with Nitrogen-Vacancy Ensembles Using Diamond Nanopillar Arrays. ACS Applied Materials & Interfaces, 2020, 12, 13421-13427.	8.0	33
13	Three-year follow-up of treatment-naÃ¯ve and previously treated patients with WaldenstrÃ¶m macroglobulinemia (WM) receiving single-agent zanubrutinib.. Journal of Clinical Oncology, 2020, 38, 8051-8051.	1.6	5
14	Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE). Blood, 2020, 136, 25-26.	1.4	4
15	Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood, 2019, 134, 851-859.	1.4	259
16	Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematology,the, 2019, 6, e459-e469.	4.6	174
17	Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study. Journal of Clinical Oncology, 2019, 37, 2815-2824.	1.6	173
18	Not All Fluorescent Nanodiamonds Are Created Equal: A Comparative Study. Particle and Particle Systems Characterization, 2019, 36, 1900009.	2.3	56

#	Article	IF	Citations
19	First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. Journal of Clinical Oncology, 2019, 37, 984-991.	1.6	183
20	The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia. Leukemia and Lymphoma, 2019, 60, 1796-1802.	1.3	20
21	Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood, 2019, 133, 299-305.	1.4	69
22	Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial. Blood, 2019, 134, 499-499.	1.4	23
23	Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial. Blood, 2019, 134, 500-500.	1.4	18
24	Magnetically sensitive nanodiamond-doped tellurite glass fibers. Scientific Reports, 2018, 8, 1268.	3.3	44
25	Epidemiology of Castleman Disease. Hematology/Oncology Clinics of North America, 2018, 32, 1-10.	2.2	62
26	Impact of Surface Functionalization on the Quantum Coherence of Nitrogen-Vacancy Centers in Nanodiamonds. ACS Applied Materials & Interfaces, 2018, 10, 13143-13149.	8.0	36
27	International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood, 2018, 132, 2115-2124.	1.4	232
28	Singleâ€agent ibrutinib versus chemoimmunotherapy regimens for treatmentâ€naÃ¯ve patients with chronic lymphocytic leukemia: A crossâ€trial comparison of phase 3 studies. American Journal of Hematology, 2018, 93, 1402-1410.	4.1	24
29	Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica, 2018, 103, 1502-1510.	3.5	111
30	Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison. Blood, 2018, 132, 5565-5565.	1.4	3
31	Bing Neel Syndrome: Retrospective Australasian Experience of a Rare Treatable Complication of WaldenstrÃ¶m Macroglobulinaemia/ Lymphoplasmacytic Lymphoma. Blood, 2018, 132, 5325-5325.	1.4	1
32	Single Centre Experience in Treating Elderly Patients with Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndrome with a Combination of Low Dose Cytarabine, Venetoclax and Fluconazole (VeLDAC-F). Blood, 2018, 132, 5220-5220.	1.4	2
33	Updated Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma. Blood, 2018, 132, 1592-1592.	1.4	6
34	Ibrutinib for the Treatment of Bing-Neel Syndrome. Blood, 2018, 132, 1609-1609.	1.4	2
35	Durable Responses in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) in a Randomised, Fludarabine-Based, Immunochemotherapy Dose De-Escalation Study - Long-Term Follow-up By Treatment Arm and Mutational Status. Blood, 2018, 132, 4432-4432.	1.4	0
36	Fixed Dose Carfilzomib Triplets in Lenalidomide Refractory Myeloma. Blood, 2018, 132, 3306-3306.	1.4	1

#	Article	IF	Citations
37	International, evidence-based consensus diagnostic criteria for HHV-8â€“negative/idiopathic multicentric Castleman disease. Blood, 2017, 129, 1646-1657.	1.4	381
38	Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncology, The, 2017, 18, 297-311.	10.7	219
39	Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology,the, 2017, 4, e534-e543.	4.6	31
40	Non-Neurotoxic Nanodiamond Probes for Intraneuronal Temperature Mapping. ACS Nano, 2017, 11, 12077-12086.	14.6	113
41	First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study.. Journal of Clinical Oncology, 2017, 35, 7500-7500.	1.6	18
42	Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2016, 17, 612-621.	10.7	214
43	Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 182-190.e1.	0.4	15
44	Scanning Nanospin Ensemble Microscope for Nanoscale Magnetic and Thermal Imaging. Nano Letters, 2016, 16, 326-333.	9.1	79
45	High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study. Blood, 2016, 128, 1216-1216.	1.4	9
46	Results of the Phase 3 Study of Lenalidomide Versus Placebo As Maintenance Therapy Following Second-Line Treatment for Patients with Chronic Lymphocytic Leukemia (the CONTINUUM Trial). Blood, 2016, 128, 230-230.	1.4	11
47	Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL. Blood, 2016, 128, 231-231.	1.4	4
48	Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. Blood, 2016, 128, 234-234.	1.4	36
49	Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). Blood, 2016, 128, 642-642.	1.4	23
50	Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2015, 373, 2425-2437.	27.0	1,261
51	Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-NaÃ¯ve CLL/SLL (RESONATE-2TM). Blood, 2015, 126, 495-495.	1.4	2
52	Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncology, The, 2014, 15, 966-974.	10.7	345
53	A Randomised Dose De-Escalation Study of Oral Fludarabine, Â±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged â‰¥65 Years: Final Analysis of Response and Toxicity. Blood, 2014, 124, 3325-3325.	1.4	13
54	Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML). Blood, 2014, 124, 519-519.	1.4	30

#	Article	IF	Citations
55	Teniposide, Cyclophosphamide, and Prednisone in Myeloma after Bortezomib and Imid Failure Is a Useful Option. Blood, 2014, 124, 5767-5767.	1.4	3
56	EPIC: A phase III trial of ponatinib (PON) versus imatinib (IM) in patients (pts) with newly diagnosed CP-CML.. Journal of Clinical Oncology, 2014, 32, 7023-7023.	1.6	3
57	Efficacy of siltuximab in patients with previously treated multicentric Castlemanâ€™s disease (MCD).. Journal of Clinical Oncology, 2014, 32, 8514-8514.	1.6	2
58	Phase 3 study of oral lenalidomide as maintenance therapy for patients with B-cell chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology, 2014, 32, TPS7125-TPS7125.	1.6	1
59	Renal Amyloidosis - Tempo of Proteinuria Resolution in Bortezomib Era. Blood, 2014, 124, 5651-5651.	1.4	0
60	Detection of atomic spin labels in a lipid bilayer using a single-spin nanodiamond probe. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 10894-10898.	7.1	113
61	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy and Safety Of Siltuximab, An Anti-Interleukin-6 Monoclonal Antibody, In Patients With Multicentric Castlemanâ€™s Disease. Blood, 2013, 122, 505-505.	1.4	7
62	Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy. Blood, 2013, 122, 509-509.	1.4	66
63	Polynesian Variant Of Idiopathic Multicentric Castleman Disease. Blood, 2013, 122, 5127-5127.	1.4	2
64	Secondary efficacy subanalysis by histology from the phase III BRIGHT study: First-line bendamustine-rituximab (BR) compared with standard R-CHOP/R-CVP for patients with advanced indolent non-Hodgkin lymphoma (NHL) or mantle cell lymphoma (MCL).. Journal of Clinical Oncology, 2013, 31, 8537-8537.	1.6	4
65	Different safety profiles of first-line bendamustine-rituximab (BR), R-CHOP, and R-CVP in an open-label, randomized study of indolent non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL): The BRIGHT study.. Journal of Clinical Oncology, 2013, 31, 8565-8565.	1.6	1
66	Differences in Quality of Life Between Bendamustine Plus Rituximab Compared with Standard First-Line Treatments in Patients with Previously Untreated Advanced Indolent Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma. Blood, 2012, 120, 155-155.	1.4	5
67	An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study. Blood, 2012, 120, 902-902.	1.4	19
68	Once Weekly Subcutanous Bortezomib with Cyclophosphamide and Dexamethasone Is Well Tolerated and Effective As Initial Treatment in Symptomatic Multiple Myeloma. Blood, 2012, 120, 4049-4049.	1.4	3
69	A Randomised Dose De-Escalation Safety Study of Oral Fludarabine, Â±Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged â‰¥65 Years â€“ End of Recruitment Analysis of Response and Toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study. Blood, 2012, 120, 436-436.	1.4	6
70	Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet, The, 2011, 377, 42-51.	13.7	957
71	Updated Results of the PRIMA Study Confirms the Benefit of 2-Years Rituximab Maintenance In Follicular Lymphoma Patients Responding to Immunochemotherapy.. Blood, 2010, 116, 1788-1788.	1.4	3
72	Thalidomide: An Active Agent in AILT Lymphoma. Blood, 2008, 112, 4960-4960.	1.4	0

#	Article	IF	Citations
73	T-Cell Depleting Antibodies. BioDrugs, 2003, 17, 147-154.	4.6	30
74	New developments in the prophylaxis and treatment of graft versus host disease. Expert Opinion on Pharmacotherapy, 2001, 2, 1109-1117.	1.8	20
75	Tresperimus: a new agent for transplant tolerance induction. Expert Opinion on Investigational Drugs, 2001, 10, 1381-1386.	4.1	6